01—Abstract
Summary
Summary of the 10-Q filed October 31, 2024. Cited figures are marked; the original filing is the authoritative source.
AMETEK, Inc. (AME) reported solid results for the third quarter and the first nine months of fiscal year 2024, demonstrating resilience and strategic execution.
For the third quarter, net sales increased by 5.3% year-over-year to $1.71 billiona, driven by contributions from recent acquisitions and favorable international demand, despite a slight organic sales decline. Diluted earnings per share remained stable at $1.47. The nine-month period showed a 6.4% increase in net sales to $5.18 billion, with diluted EPS rising to $4.26.
The company's strong operational performance, coupled with effective integration of its 2023 acquisitions, particularly Paragon Medical and United Electronic Industries, contributed positively to financial results. Financially, AMETEK maintained a strong liquidity position, with operating cash flow increasing by 7.0% to $1.28 billionb for the first nine months.
The company also demonstrated a commitment to returning capital to shareholders, increasing its quarterly dividend by 12% and repurchasing $68.0 millionc in common stock during the period. The debt-to-capital ratio improved significantly to 19.7% from 27.5% at the end of the previous year, highlighting a strengthened balance sheet.
02—Key points
Key Highlights
- Net sales for Q3 2024 increased 5.3% to $1.71 billion, driven by acquisitions and international growth, while nine-month sales rose 6.4% to $5.18 billion.
- Diluted EPS for Q3 2024 was $1.47 (flat year-over-year), and for the nine-month period, it increased to $4.26 ($4.19 in prior year).
- Operating income for Q3 2024 grew 1.8% to $445.9 million, and for the nine-month period, it increased 3.8% to $1.31 billion.
- Operating cash flow for the nine-month period increased 7.0% to $1.28 billion, and free cash flow was $1.20 billion.
- The company increased its quarterly cash dividend by 12% to $0.28 per share.
- Debt-to-capital ratio improved to 19.7% as of September 30, 2024, down from 27.5% at December 31, 2023.
- Acquisitions, including Paragon Medical and Amplifier Research, contributed significantly to sales growth, although they had a dilutive impact on segment operating margins in the short term.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, Ametek Inc kept $0.20.
- Revenue$1.71B100.0%
- Cost of revenue−$1.09B64.0%
- Gross profit$615.8M36.0%
- Operating costs−$170.0M9.9%
- Operating income$445.9M26.1%
- Interest, other & tax−$105.6M6.2%
- Net income$340.2M19.9%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed October 31, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $1.71B$1.62B | +5.3% |
| Cost of Revenue | $1.09B$1.02B | +7.0% |
| Gross Profit | $615.81M$601.92M | +2.3% |
| SG&A Expenses | $169.96M$163.78M | +3.8% |
| Operating Expenses | $1.26B$1.18B | +6.6% |
| Operating Income | $445.85M$438.13M | +1.8% |
| Net Income | $340.24M$340.37M | 0.0% |
| EPS (Basic) | $1.47$1.48 | −0.7% |
| EPS (Diluted) | $1.47$1.47 | 0.0% |
| Shares Outstanding (Basic) | 231.34M230.69M | +0.3% |
| Shares Outstanding (Diluted) | 232.22M231.75M | +0.2% |
05—Questions
Frequently Asked Questions
What was the primary driver of AMETEK's sales growth in the third quarter?
AMETEK's sales growth in the third quarter of 2024 was primarily driven by contributions from recent acquisitions, which accounted for a 7% increase. This was partially offset by a 2% organic sales decline. International sales also showed strength, increasing by 11.2%.
How did the company's profitability fare in this quarter?
For the third quarter of 2024, AMETEK reported net income of $340.2 million, which was flat compared to the prior year's $340.4 million. Diluted earnings per share also remained flat at $1.47. Operating income saw a slight increase of 1.8% to $445.9 million. While overall net income was stable, the company noted that the dilutive impact of recent acquisitions and foreign currency headwinds negatively affected operating margins.
What is the company's stance on capital allocation, specifically dividends and share buybacks?
AMETEK continues to return capital to shareholders. In February 2024, the company announced a 12% increase in its quarterly cash dividend to $0.28 per share. Additionally, during the first nine months of 2024, AMETEK repurchased $68.0 million of its common stock.
How has AMETEK's financial health improved, particularly regarding its debt?
AMETEK has significantly improved its financial health. The debt-to-capital ratio decreased to 19.7% as of September 30, 2024, down from 27.5% at the end of 2023. The net debt-to-capital ratio also improved to 16.9%. This strengthening of the balance sheet is partly due to paying off a $300 million senior note in the third quarter and robust operating cash flow generation.
06—Continue